Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Population genomics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Population genomics. Displaying page 1 of 1.
    EudraCT Number: 2018-002140-88 Sponsor Protocol Number: CL04-ORY-2001 Start Date*: 2018-09-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer’s Disease (AD), Lewy Body Dementia (LBD)...
    Medical condition: Agression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001488 Aggression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001436-54 Sponsor Protocol Number: CL06-ORY-2001 Start Date*: 2019-06-05
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A single-center, open-label, single-arm, 13-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in Alzheimer’s Disease (AD) – REIMAGINE-AD
    Medical condition: Aggression in Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-007943-29 Sponsor Protocol Number: EFC6521 Start Date*: 2008-07-29
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk ...
    Medical condition: The subjects who will participate to this clinical trial are cancer patients (i.e. patients with metastatic or locally advanced tumor of the lung, pancreas, stomach, colon/ rectum, bladder or ovary...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FR (Completed) AT (Completed) LV (Completed) EE (Completed) SE (Completed) SK (Completed) NL (Completed) PT (Completed) LT (Completed) BE (Completed) DK (Completed) CZ (Completed) FI (Completed) SI (Completed) IT (Completed) BG (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003469-20 Sponsor Protocol Number: CL07-ORY-2001 Start Date*: 2020-11-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (POR...
    Medical condition: Borderline Personality Disorder (BPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-001455-32 Sponsor Protocol Number: WIN001 Start Date*: 2017-12-15
    Sponsor Name:Worldwide Innovative Network Association
    Full Title: A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to mat...
    Medical condition: Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (EGFR mutation, ALK translocation, ROS1 mutation if available or MET exon 14 skipping ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000469-35 Sponsor Protocol Number: CL03-ORY-1001SCLC Start Date*: 2018-10-10
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cel...
    Medical condition: Relapsed, extended-stage disease small cell lung cancer (ED SCLC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002422-36 Sponsor Protocol Number: INCB54828-202 Start Date*: 2017-05-04
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including F...
    Medical condition: Subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocations, with other FGF/FGFR alterations, or who are negative for any FGF/FGFR alterations, who fai...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001311-36 Sponsor Protocol Number: R2810-ONC-16113 Start Date*: 2018-02-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patie...
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) LT (Completed) IT (Completed) AT (Completed) PL (Trial now transitioned) HR (Completed) GR (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003651-11 Sponsor Protocol Number: R668-AD-1021 Start Date*: 2013-06-10
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study investigating the efficacy, safety, pharmacokinetic and biomarker profiles of Dupilumab (REGN668) administered to ...
    Medical condition: Atopic dermatits
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002827-15 Sponsor Protocol Number: A3671009 Start Date*: 2006-01-19
    Sponsor Name:Pfizer Ltd. [...]
    1. Pfizer Ltd.
    2.
    Full Title: Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025650 VTc
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) BE (Completed) SE (Completed) GR (Completed) CZ (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003836-29 Sponsor Protocol Number: R668-AD-1117 Start Date*: 2012-02-28
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, double-blind, placebo-controlled, repeat-dose study of the efficacy, safety, tolerability, and pharmacodynamics of subcutaneously-administered REGN668 in adult patients with extrinsic...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-002322-20 Sponsor Protocol Number: PA0010 Start Date*: 2019-06-26
    Sponsor Name:UCB Biopharma SRL
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE ...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) HU (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001468-23 Sponsor Protocol Number: TG4010.14 Start Date*: 2011-12-19
    Sponsor Name:Transgene S.A.
    Full Title: A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NS...
    Medical condition: Stage IV non small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    19.0 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006439-12 Sponsor Protocol Number: INSIGHT001:STARTDAIDSID#10619 Start Date*: 2009-05-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: Strategic Timing of AntiRetroviral Treatment(START)
    Medical condition: HIV Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) SE (Completed) PT (Completed) IE (Completed) EE (Completed) NO (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-002542-16 Sponsor Protocol Number: INSIGHT013 Start Date*: 2020-09-30
    Sponsor Name:Office of Sponsored Projects, Regents of the University of Minnesota
    Full Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the...
    Medical condition: COVID-19 (SARS-CoV-2) infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001663-24 Sponsor Protocol Number: INSIGHT012 Start Date*: 2021-09-20
    Sponsor Name:Office of Sponsored Projects,University of Minnesota
    Full Title: An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Out...
    Medical condition: We are investigating Coronavirus disease 2019 (COVID-19) which is predominantly a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:25:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA